Pharscin Pharmaceutical Receives Clinical Trial Approval for Glaucoma Eye Drop Candidate

Stock News

Aug 13

Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) announced that its controlled subsidiary, Chengdu Huasen Aorui Pharmaceutical Co., Ltd. (Huasen Aorui), has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA) for Phosphoric ORIC-1327 Eye Drops. The approval covers two indications across six specifications.

Phosphoric ORIC-1327 Eye Drops (Project Code: ORIP-1009) is a selective small molecule inhibitor independently developed by Huasen Aorui, with full independent intellectual property rights. It is clinically intended for the treatment of glaucoma and ocular hypertension. Preclinical studies have confirmed the drug's significant intraocular pressure-lowering effects in New Zealand rabbits and cynomolgus monkeys, along with good ocular safety, demonstrating promising drug development prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1115860913"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1115860913\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1115860913?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 16:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115860913","market":"nz","top_or_hot":-1,"title":"Pharscin Pharmaceutical Receives Clinical Trial Approval for Glaucoma Eye Drop Candidate","media":"Stock News","content":"<p><b>Chongqing Pharscin Pharmaceutical Co.,Ltd.</b> (002907.SZ) announced that its controlled subsidiary, Chengdu Huasen Aorui Pharmaceutical Co., Ltd. (Huasen Aorui), has received the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA) for Phosphoric ORIC-1327 Eye Drops. The approval covers two indications across six specifications.<br><br>Phosphoric ORIC-1327 Eye Drops (Project Code: ORIP-1009) is a selective small molecule inhibitor independently developed by Huasen Aorui, with full independent intellectual property rights. It is clinically intended for the treatment of glaucoma and ocular hypertension. Preclinical studies have confirmed the drug's significant intraocular pressure-lowering effects in New Zealand rabbits and cynomolgus monkeys, along with good ocular safety, demonstrating promising drug development prospects.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharscin Pharmaceutical Receives Clinical Trial Approval for Glaucoma Eye Drop Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharscin Pharmaceutical Receives Clinical Trial Approval for Glaucoma Eye Drop Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-13 16:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Chongqing Pharscin Pharmaceutical Co.,Ltd.</b> (002907.SZ) announced that its controlled subsidiary, Chengdu Huasen Aorui Pharmaceutical Co., Ltd. (Huasen Aorui), has received the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA) for Phosphoric ORIC-1327 Eye Drops. The approval covers two indications across six specifications.<br><br>Phosphoric ORIC-1327 Eye Drops (Project Code: ORIP-1009) is a selective small molecule inhibitor independently developed by Huasen Aorui, with full independent intellectual property rights. It is clinically intended for the treatment of glaucoma and ocular hypertension. Preclinical studies have confirmed the drug's significant intraocular pressure-lowering effects in New Zealand rabbits and cynomolgus monkeys, along with good ocular safety, demonstrating promising drug development prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMED","symbol_name":"iShares Health Innovation Active ETF","start_time":0,"source_url":"","article_id":"1115860913","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115860913","pubTimestamp":1786608136,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) announced that its controlled subsidiary, Chengdu Huasen Aorui Pharmaceutical Co., Ltd. (Huasen Aorui), has received the \"Drug Clinical Trial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMED":"iShares Health Innovation Active ETF","BK0239":"医药制造","IBBQ":"Invesco Nasdaq Biotechnology ETF","MDTX":"Corgi MediaTek 2x Daily ETF","002907":"华森制药","PSYK":"PSYK ETF","ORIC":"Oric Pharmaceuticals Inc.","BK4139":"生物科技","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF"},"translate_title":"Pharscin Pharmaceutical 获得青光眼眼药水候选药物临床试验批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMED":1,"PSYK":1,"IBBJ":1,"ORIC":1,"002907":1,"IBBQ":1,"MDTX":1},"content_text":"Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) announced that its controlled subsidiary, Chengdu Huasen Aorui Pharmaceutical Co., Ltd. (Huasen Aorui), has received the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA) for Phosphoric ORIC-1327 Eye Drops. The approval covers two indications across six specifications.Phosphoric ORIC-1327 Eye Drops (Project Code: ORIP-1009) is a selective small molecule inhibitor independently developed by Huasen Aorui, with full independent intellectual property rights. It is clinically intended for the treatment of glaucoma and ocular hypertension. Preclinical studies have confirmed the drug's significant intraocular pressure-lowering effects in New Zealand rabbits and cynomolgus monkeys, along with good ocular safety, demonstrating promising drug development prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}